|
Parameter
|
Univariable analyses
|
Multivariable analyses
|
|---|
| |
No recurrence
|
Recurrence
|
HR (95 % CI)
|
p value
|
HR (95 % CI)
|
p value
|
|---|
|
Tumor grade
| | | |
0.041
| |
0.353
|
|
G1 + G2
|
69
|
32
|
1.00
|
1.00
|
|
G3
|
70
|
52
|
1.534 (1.017-2.314)
|
1.278 (0.762-2.142)
|
|
PR (biopsy)
| | | |
0.034
| |
0.002
|
|
Negative
|
58
|
46
|
1.00
|
1.00
|
|
Positive
|
91
|
43
|
0.655 (0.443-0.968)
|
0.448 (0.268-0.748)
|
|
cT pretreatment
| | | |
0.001
| |
0.002
|
|
cT1 + cT2
|
100
|
37
|
1.00
|
1.00
|
|
cT3 + cT4
|
44
|
49
|
1.955 (1.309-2.919)
|
2.244 (1.342-3.750)
|
|
pN (tumor)
| | | | | | |
|
pN0
|
72
|
19
|
1.00
| |
1.00
| |
|
pN1
|
60
|
52
|
3.255 (1.929-5.492)
|
<0.001
|
2.813 (1.440-5.496)
|
<0.002
|
|
pN2 + pN3
|
15
|
18
|
4.003 (2.057-7.788)
|
<0.001
|
6.793 (3.070-15.030)
|
<0.001
|
|
NLR
|
150
|
95
|
0.978 (0.932-1.026)
|
0.363
|
1.009 (0.957-1.064)
|
0.738
|
- Abbreviations: CI confidence interval, cT clinical tumor size, NLR neutrophil lymphocyte ratio, HR hazard ratio, PR progesterone receptor
